Upstream Bio, Inc. (UPB) reported positive results from Phase 2 VIBRANT study on verekitug for chronic rhinosinusitis with nasal polyps. The study met primary goal with significant reduction in nasal polyp score and congestion score. Verekitug was well tolerated with no serious adverse events observed.

Read more at Nasdaq: Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study